Covarrubias AJ, Kale A, Perrone R, et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages [J]. Nature Metabolism. 2020, 2(11):1265-83.
 Chini CC, Peclat TR, Warner GM, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels [J]. Nature Metabolism. 2020, 2(11):1284-304.
 Mehta, K., Shahid, U., & Malavasi, F. Human CD38, a cell-surface protein with multiple functions [J]. FASEB journal. 1996, 10(12): 1408-1417.
 Durnin L, Mutafova‐Yambolieva VN. Cyclic ADP-ribose requires CD38 to regulate the release of ATP in visceral smooth muscle [J]. FEBS. 2011, 278(17): 3095-108.
 Chini EN. CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions [J]. Current pharmaceutical design. 2009, 15(1):57-63.
 Navazio L, Mariani P, Sanders D. Mobilization of Ca2+ by cyclic ADP-ribose from the endoplasmic reticulum of cauliflower florets [J]. Plant Physiology. 2001, 1; 125(4):2129-38.
 Morandi F, Airoldi I, Marimpietri D, Bracci C, Faini AC, Gramignoli R. CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies [J]. Cells. 2019, 8(12):1527.
 Glaría E, Valledor AF. Roles of CD38 in the Immune Response to Infection [J]. Cells. 2020, 9(1):228.
 Guerreiro S, Privat AL, Bressac L, Toulorge D. CD38 in Neurodegeneration and Neuroinflammation [J]. Cells. 2020, 9(2):471.
 Cole S, Walsh A, Yin X, Wechalekar MD, et al. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus [J]. Arthritis research & therapy. 2018, 20(1):1-4.
 Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? [J]. Aids. 2000, 14(9):1079-89.
 van de Donk NW, Janmaat ML, et al. Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond [J]. Immunological reviews. 2016, 270(1):95-112.
 Dürig J, Naschar M, Schmücker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia [J]. Leukemia. 2002, 16(1):30-5.
 Paulus A, Manna A, Akhtar S, et al. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells [J]. British Journal of Haematology. 2018, 183(2):196-211.
 Roccatello D, Fenoglio R, Sciascia S, et al. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond [J]. International Journal of Molecular Sciences. 2020, 21(11):4129.
 Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification [J]. Blood. 2015, 23; 126 (4):454-62.
 Naik J, Themeli M, de Jong-Korlaar R, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia [J]. Haematologica. 2019, 104(3):e100.
 George AA, Franklin J, Kerkof K, et al. Detection of leukemic cells in the CD34+ CD38− bone marrow progenitor population in children with acute lymphoblastic leukemia [J]. Blood, the Journal of the American Society of Hematology. 2001, 97(12):3925-30.
 Mallone R, Funaro A, Zubiaur M, et al. Signaling through CD38 induces NK cell activation [J]. International immunology. 2001, 13(4):397-409.
 Morandi F, Horenstein AL, Costa F, et al. CD38: a target for immunotherapeutic approaches in multiple myeloma [J]. Frontiers in immunology. 2018, 9:2722.
 Fang C, Li T, Li Y, et al. CD38 produces nicotinic acid adenosine dinucleotide phosphate in the lysosome [J]. Journal of Biological Chemistry. 2018, 293(21):8151-60.
 Janmaat ML, van de Donk NW, van Bueren JL, et al. Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab. Successful Drug Discovery. 2018, 3:153-95.
 Konen JM, Fradette JJ, Gibbons DL. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors [J]. Cells. 2020, 9(1):52.